Why IBIO matters now
iBio, Inc. (IBIO) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.40 with -2.10% on the session and $22.1M in market capitalization; recent performance reads 1-month +12.67% and YTD -12.44%.
The latest financial table shown here is Q3 2026, with revenue of $0.00, net income of $-7.7M, and EPS of $-0.06. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -83.1%.
The latest indexable market news headline is "iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $5.00; recent insider activity includes Stoner Elizabeth filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.61
P/S
88.95
EV/EBITDA
0.71
DCF Value
$0.25
FCF Yield
-83.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
-160.0%
Operating Margin
-7985.3%
Net Margin
-9202.0%
ROE
-53.9%
ROA
-32.2%
ROIC
-30.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $0.00 | $-7.7M | $-0.06 |
| Q2 2026 | $0.00 | $-9.0M | $-0.09 |
| Q1 2026 | $100.0K | $-5.7M | $-0.11 |
| Q4 2025 | $200.0K | $-5.2M | $-0.31 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$5.00
Target (Median)
$5.00
Target Range
$5.00 - $5.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.27
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.